Answers are grounded in this paper and cite their sources.
HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: